重组因子IX Fc用于治疗B型血友病的治疗
Rolf Ljung1, Davide Matino2, Amy D Shapiro3
1Department of Clinical Sciences-Pediatrics, Lund University, Lund, Sweden.
European journal of haematology
|February 19, 2024
概括
延长半衰期的第九因子 (FIX) 替代剂,rFIXFc,通过extravascularly支持血液静止提供有效的血友病B预防. 它的安全性和有效性已经在各种患者群体中得到了很好的证实.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 目前的B型血友病治疗依赖于针对血水平的因子IX (FIX) 预防.
- 由于血管外分布,血FIX活性可能不能完全反映出静血疗效.
- 延长半衰期 (EHL) FIX产品提供长时间的出血保护.
研究的目的:
- 审查rFIXFc.的药理动力学特征.
- 为了总结rFIXFc预防的安全性和有效性数据.
- 评估rFIXFc在特殊人群中的使用,并讨论未来的治疗挑战.
主要方法:
- 对rFIXFc.的药理动力学数据的审查.
- 关于rFIXFc安全性和有效性的临床试验和现实世界的综合证据.
- 分析B型血友病的治疗挑战和EHL产品的作用.
主要成果:
- rFIXFc显示出延长的循环时间和外血管分布.
- rFIXFc预防在成年人,青少年和儿童,包括以前未接受过治疗的患者中是安全有效的.
- 证据支持rFIXFc在不同患者群体中治疗血友病B的作用.
结论:
- rFIXFc独特的生物分布可能会独立于血FIX水平而增强血静.
- rFIXFc提供了一种成熟且有效的预防性选择,用于B型血友病.
- 像rFIXFc这样的EHL产品对于解决当前和未来的血友病B治疗挑战至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Recombinant DNA
94.5K
Overview
94.5K
Extrinsic and Intrinsic Pathways of Hemostasis
7.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.6K
Clot Retraction and Fibrinolysis
5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
Coagulation
6.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.6K


